Hamburg City Health Study - a German Cohort Study

Study Purpose

The Hamburg City Health Study (HCHS) is a large, prospective, long-term, population-based cohort study and a unique research platform and network to obtain substantial knowledge about several risk and prognostic factors in major chronic diseases.

Recruitment Criteria

Accepts Healthy Volunteers Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms	Yes
Study Type An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies.	Observational
Eligible Ages	45 Years - 74 Years
Gender	All

More Inclusion & Exclusion Criteria

Inclusion Criteria:

- Inhabitant of the city of Hamburg at the time of inclusion into the study (Inclusion is time of written consent) - Age 45 to 74 years.

- Personally signed informed consent.

Exclusion Criteria:

- Insufficient knowledge of the German language, in order to understand study documents and computer assisted interview without translation.

- Physical or psychological incapability to travel to the study center and to cooperate in the investigations

Trial Details

Trial ID: This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.	NCT03934957
Phase Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
Lead Sponsor The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.	Universitätsklinikum Hamburg-Eppendorf
Principal Investigator The person who is responsible for the scientific and technical direction of the entire clinical study.	Stefan Blankenberg, Professor
Principal Investigator Affiliation	Universitäres Herzzentrum Hamburg
Agency Class Category of organization(s) involved as sponsor (and collaborator) supporting the trial.	Other
Overall Status	Recruiting
Countries	Germany
Conditions The disease, disorder, syndrome, illness, or injury that is being studied.	Coronary Heart Disease, Stroke, Dementia, Cancer, Health Care, Vascular Diseases, Periodontal Diseases, Ocular Diseases, Respiratory Disease, Obesity
Study Website:	View Trial Website

Additional Details

A random sample of 45.000 participants between 45 and 74 years of age from the general population of Hamburg, Germany, will take part in an extensive baseline assessment at a dedicated study center. Participants undergo 13 validated and 5 novel examinations primarily targeting cardiac, arterio-venous and cerebral function and structure including extensive imaging examinations. The protocol includes self-ratings of life style and environmental conditions, , dietary habits, physical activity, professional life, psychosocial context, , digital media use, medical and family history as well as health care utilization patterns. The assessment is completed by genomic and proteomic characterization. Beyond the identification of classical risk factors for major chronic diseases and survivorship, the core intention is to develop complex models predicting health outcomes based on a multitude of examination data, imaging data and behavioral assessments. Participants at risk for coronary artery disease, atrial fibrillation, heart failure, stroke and dementia will be invited for a visit to conduct additional MRI examination either of heart or brain. Endpoint assessment of the overall sample will be completed through repeated follow-up examinations and data from involved health and pension insurances.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Universitätsklinikum Hamburg-Eppendorf, Hamburg 2911298, Germany

Status

Recruiting

Address

Universitätsklinikum Hamburg-Eppendorf

Hamburg 2911298, , 20246

Site Contact

Susannw Bruder

[email protected]

00494056045

Clinical Trial Finder